Haematologica Reports 2006; 2: issue 7
New Insights in Hematology
THE NEW ERA IN THE TREATMENT OF NON-HODGKIN’S LYMPHOMA
Nuclear medicine perspective on radioimmunotherapy
S. Fanti, G. Montini, M. Farsad
Target long-term responders in indolent non-Hodgkin’s lymphoma: 90Y-ibritumomabtiuxetan
C. Emmanouilides
Impact of radioimmumotherapy on aggressive non-Hodgkin’s lymphoma
P.L. Zinzani
Novel pathogenetic mechanisms and therapeutic targets in B cell lymphomas
R. Dalla-Favera
HODGKIN’S LYMPHOMA
Hodgkin’s Lymphoma and Grey-zone Lymphomas
F. Facchetti, M. Ungari, A. Ubiali
Incorporation of PET scanning into contemporary management programs for Hodgkin’s disease
R.T. Hoppe
Current directions in the treatment of early stage Hodgkin’s lymphoma
D.J. Straus
Combined modality treatment for early-stage Hodgkin’s lymphoma: the GHSG experience
S. Sasse, V. Diehl, A. Engert
Management of advanced Hodgkin's lymphoma
G.P. Canellos
CHRONIC LYMPHOCYTIC LEUKEMIA
Dissecting the natural history of chronic lymphocytic leukemia to discover new therapeutic targets
F. Caligaris-Cappio, C. Scielzo, M. Muzio, R.M. Carletti, A. Camporeale, M. Frenquelli, C. Fazi, M. Alessio, A. Bachi, P. Ghia
Monoclonal antibodies in the treatment of chronic lymphocytic leukemia
M.J. Keating
IMPROVING OUTCOME IN MULTIPLE MYELOMA
AND NON-HODGKIN’S LYMPHOMA
New approaches to front-line therapy in multiple myeloma patients aged over 60 year
J.F. San-Miguel, M.V. Mateos
Practical issues involved with the use of bortezomib
S. Lonial
Improving the treatment paradigm for non-Hodgkin’s lymphoma with bortezomib
P.L. Zinzani
LOW GRADE NON-HODGKIN’S LYMPHOMA
The prognosis of follicular lymphomas: the F2-project
M. Federico, M. Bellei, B. Pro, A. Lopez-Guillermo, U. Vitolo, S. Luminari, S. Pileri, P. Solal-Céligny
The evolution of follicular and the relevance of transformation to DLBCL
A. Lister
Reduced Intensity Allogeneic Transplant for Low Grade Non Hodgkin’s Lymphoma
A.H.Goldstone
NEW DRUGS
Development of a predictive model for tumour lysis syndrome in patients with acute myeloid leukemia
P. Montesinos
Palonosetron, second generation 5-HT3 antagonist: a new perspective in CINV management
P.P. Piccaluga
Azacytidine: first therapeutic opportunity for myelodysplastic syndromes
C. Finelli, C. Bosi, G. Martinelli, M. Baccarani
Posaconazole: a new option for invasive fungal infection management
A. Nosari
Liposomal doxorubicin: emergent data in lymphoproliferative disease
L. Rigacci
LARGE CELL NON-HODGKIN’S LYMPHOMA
Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals two
distinct subgroups and recurrent pdgfr-a deregulation
S.A. Pileri, P.P. Piccaluga, C. Agostinelli, S. Zupo, F. Facchetti, B. Falini, M. Ferrarini, A. Gallamini, D. Novero, M. Paulli, P. Zinzani, R. Dalla Favera
Molecular pathogenesis of diffuse large B-celllymphoma
G. Saglio, M. Bosa, M. Gino, S. Ulisciani, G. Parvis
Progress in the treatment of diffuse large B-cell lymphomas: a German perspective
M. Pfreundschuh
What will be the future after R-CHOP in patient with DLBCL?
B. Coiffier
High-dose therapy. Experience of the non-Hodgkin’s lymphoma Co-operative Study Group (NHLCSG)
G. Santini
Reduced-intensity allogeneic stem cell transplantation is an effective salvage treatment for relapsed aggressive non-Hodgkin’s lymphoma
P. Corradini, A. Dodero, M. Bregni, A. Olivieri, P. Valagussa, L. Farina, R. Milani, R. Scimé, A. Rambaldi, F. Bonifazi, F. Patriarca, A. Locasciulli, A. Bacigalupo, A.M. Gianni, C. Tarella
ENHANCING, RESULTS IN NON-HODGKIN’S LYMPHOMA
How important is to eradicate minimal residual disease in indolent non-Hodgkin’s lymphoma?
A. Rambaldi
Follicular lymphoma: maintenance strategies in the spotlight
M.H.J. van Oers
The effect of adding rituximab to high dose chemotherapy
U. Vitolo, A. Chiappella, G. Rossi, E. Angelucci, M. Liberati, E. Gallo
BONE MARROW TRANSPLANTATION
High-dose sequential chemotherapy versus a less intensive regimen followed by peripheral blood autologous hematopoietic stem cell transplantation as salvage treatment in relapsed and refractory Hodgkin’s disease
J.T. Souto Filho, A.C. Vigorito, K.P. Urago, S.F. Matte, E.A. Miranda, M. Delamain, I. Lorand-Metze, C.M. Duarte, G.B. Oliveira, K.B. Pagnano, A. Maiolino, M. Nucci, C.A. De Souza
Allogeneic transplantation for multiple myeloma
I. Majolino, E. Carnevall, A. Locasciulli P. Di Bartolomeo, R. Scimè, P. Corradini, C. Selleri
F. Narni, M. Musso, M. Bregni, A. Olivieri, P. De Fabritiis, L. Pogliani, J.E. Duque-Arbelaez
C. Ruscio, A. Bacigalupo
Risk assessment for multiple myeloma: the role of bone marrow transplantation
A. Maiolino
Tandem transplant in oncohematology
A.M. Carella
Transplantation for low grade lymphoma
J.G. Gribben
NOVEL STRATEGIES IN SUPPORTIVE CARE
The value of PegFilgastrim for the therapy of acute myeloid leukemia
A. Ciolli, F. Leoni, A. Bosi
Palifermin, the first specific drug treatment for oral mucositis in bone marrow transplant
E. Gallo
MULTIPLE MYELOMA
Interactions between myeloma cells and bone microenvironment
N. Giuliani, F. Morandi, S. Tagliaferri, V. Rizzoli
Unconventional properties of zoledronic acid
M. Massaia, F. Fiore, B. Castella, F. Pantaleoni, S. Mariani, S. Peola, S.Y. Hwang, G. Matta
M. Foglietta, M. Coscia, M. Boccadoro
The impact of new drugs in the high dose strategy
M. Attal
Emerging role for reduced intensity allotransplant in multiple myeloma
B. Bruno, M. Boccadoro
New treatment strategies for elderly myeloma patients
A. Palumbo, P. Falco, P. Musto, G. Rossi, N. Giuliani, F. Morabito, A. Falcone, F. Gay, I. Avonto, M.T. Ambrosini, R. Capozzi, V. Callea, C. Cangialosi, M. Montanaro, L. Catalano, M. Grasso, M.C. Petti, M. Merla, L. Falchi, M.T. Petrucci, T. Caravita, S. Bringhen, P. Corradini, F. Di Raimondo, M. Boccadoro